Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Ocaliva (obeticholic acid) - Important Safety Information from Intercept as approved by the HPRA
Notice type:
3rd Party Publications
Date:
09/02/2018
Problem Or Issue:
Important Safety Information communication from Intercept: Ocaliva (obeticholic acid) - Reinforced differential dosing recommendations for OCALIVA in primary biliary cholangitis (PBC) patients with moderate and severe hepatic impairment.
Important Safety Information - Ocaliva (obeticholic acid)
« Back
Date Printed: 25/04/2024